NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) ...
Sept. 15, 2005 — The U.S. Food and Drug Administration (FDA) has approved nepafenac 0.1% ophthalmic suspension for the treatment of pain and inflammation associated with cataract surgery; a sugar-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results